

PTE-1449 REPRODUCED

ATTORNEY DOCKET NO.
089/US/PCT2/US-AAPPLICATION NO.
10/629,261INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(USE several sheets if necessary)

APPLICANT
DONG, Zheng Xin.FILING DATE
July 28, 2003GROUP/EXAMINER
1654/Lukton, David

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
DA	00/34331	Jun. 15, 2000	PCT			
X DB	HU P9501508	Feb. 28, 1997	Hungary			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DC	ADELHORST, K. et al., "Structure-activity studies of glucagon-like peptide-1," 1994, J. Biological Chemistry, 269(9):6275-6278.
DD	AHREN, Bo, et al.; "Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus"; 1997; Journal of Clinical Endocrinology and Metabolism; Vol. 82:2; Pages 473-478
DE	DEACON, C.F., et al.; "Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity"; 1998; Diabetologia; Vol. 41; Pages 271-278
DF	DEACON, C.F., et al.; "Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig"; 1998; Diabetes; Vol. 47; Pages 764-769
DG	GUTNIAK, Mark, et al.; "Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus"; 1992; The New England Journal of Medicine; Vol. 326; Pages 1316-1322
DH	MENTLEIN, R., et al.; "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum"; 1993; Biochem; Vol. 214; Pages 829-835
DI	NAUCK, M.A., et al.; "Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM"; 1996; Diabetologia; Vol. 39:2; Pages 1546-1553
DJ	RACHMAN, J., et al.; "Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM"; 1997; Diabetologia; Vol. 40; Pages 205-211
DK	RITZEL, U. et al., "A synthetic glucagon-like peptide-1 analog with improved plasma stability," 1998, J. Endocrinology, 159:93-102.
DL	SUZUKI, S., et al.; "Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptides of Glucagon-Like Peptide-1 on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas"; 1989; Endocrinology; Vol. 125:6; Pages 3109-3114

EXAMINER

DATE CONSIDERED

David Lukton

7-25-06

PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
089/US/PCT2/US-AAPPLICATION NO.
10/629,261APPLICANT
DONG, Zheng Xin.FILING DATE
July 28, 2003GROUP/EXAMINER
1654/Lukton, David**U.S. PATENT DOCUMENTS**

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DM	THORENS, Bernard, et al.; "Structure and Function of the Glucagon-Like Peptide-1 Receptor"; 1996; Journal: Handbook of Experimental Pharmacology; Vol. 123; Pages 255-273
DN	TODD, J.F., et al.; "Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus"; 1997; European Journal of Clinical Investigation; Vol. 27; Pages 533-536

EXAMINER

David Lukton

DATE CONSIDERED

7-25-06